Want to see QTRX full AI Analyst Report?
QTRX Stock Chart & Stats
$2.79
-$0.25(-2.12%)
At close: 4:00 PM EST
$2.79
-$0.25(-2.12%)
Day’s Range― - ―
52-Week Range$2.15 - $8.77
Previous CloseN/A
Volume125.22K
Average Volume (3M)792.38K
Market Cap
$128.64M
Enterprise Value$143.62M
Total Cash (Recent Filing)$93.53M
Total Debt (Recent Filing)$33.39M
Price to Earnings (P/E)―
Beta1.00
Next Earnings
Nov 10, 2026EPS Estimate
-0.42Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.63
Shares Outstanding47,293,064
10 Day Avg. Volume461,896
30 Day Avg. Volume792,375
Financial Highlights & Ratios
PEG Ratio-0.02
Price to Book (P/B)0.92
Price to Sales (P/S)1.96
P/FCF Ratio-3.40
Enterprise Value/Market Cap1.12
Enterprise Value/Revenue0.94
Enterprise Value/Gross Profit2.20
Enterprise Value/Ebitda-1.46
Forecast
1Y Price Target
$3.25Price Target Upside16.49% Upside
Rating ConsensusHold
Number of Analyst Covering2
EPS Forecast (FY)-2.24
Revenue Forecast (FY)$143.82M
Bulls Say, Bears Say
Bulls Say
Akoya Cost SynergiesCompleting the Akoya integration and realizing $85 million of annualized savings improves the combined cost structure and demonstrates tangible execution on the acquisition. If sustained, these savings can support margins, reduce ongoing cash consumption, and provide capacity to fund commercial priorities.
Gross Margin ImprovementThe substantial year-over-year improvement in non-GAAP gross margin indicates that Quanterix is making progress on profitability despite weak revenue conditions. A higher underlying margin can strengthen the economics of its instrument, assay, and consumables ecosystem as demand and utilization recover.
Diagnostics Reimbursement ProgressCMS pricing and Anthem coverage are structural milestones for LucentAD Complete because reimbursement improves customer access and supports broader clinical adoption. Greater coverage can help convert Quanterix's diagnostic technology into a more scalable commercial opportunity beyond research markets.
Bears Say
Lower Revenue OutlookThe material reduction in full-year revenue guidance signals that commercial execution and demand are weaker than previously expected. A lower revenue base can delay operating leverage, limit near-term growth investment, and make the path toward sustainable profitability more dependent on cost actions.
Persistent Cash BurnContinued negative operating and free cash flow means the business is not yet funding itself internally, while the deterioration from 2024 indicates rising financing needs. This reduces strategic flexibility and leaves less financial capacity to absorb further weakness or invest in growth.
Severe Operating LossesSharp gross-margin compression combined with a deeply negative EBIT margin shows that current revenue is insufficient to support the cost base. Unless pricing, mix, or operating efficiency improves durably, ongoing losses can erode equity and postpone the transition to profitable growth.
Quanterix News
QTRX FAQ
What was Quanterix Corporation’s price range in the past 12 months?
Quanterix Corporation lowest stock price was $2.15 and its highest was $8.77 in the past 12 months.
What is Quanterix Corporation’s market cap?
Quanterix Corporation’s market cap is $128.64M.
When is Quanterix Corporation’s upcoming earnings report date?
Quanterix Corporation’s upcoming earnings report date is Nov 10, 2026 which is in 18 days.
How were Quanterix Corporation’s earnings last quarter?
Quanterix Corporation released its earnings results on Aug 10, 2026. The company reported -$1.04 earnings per share for the quarter, missing the consensus estimate of -$0.41 by -$0.63.
Is Quanterix Corporation overvalued?
According to Wall Street analysts Quanterix Corporation’s price is currently Undervalued.
Does Quanterix Corporation pay dividends?
Quanterix Corporation does not currently pay dividends.
What is Quanterix Corporation’s EPS estimate?
Quanterix Corporation’s EPS estimate is -0.42.
How many shares outstanding does Quanterix Corporation have?
Quanterix Corporation has 47,293,064 shares outstanding.
What happened to Quanterix Corporation’s price movement after its last earnings report?
Quanterix Corporation reported an EPS of -$1.04 in its last earnings report, missing expectations of -$0.41. Following the earnings report the stock price went down -39.95%.
Which hedge fund is a major shareholder of Quanterix Corporation?
Currently, no hedge funds are holding shares in QTRX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Quanterix Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$3.25 (16.49% Upside)
$3.25 (16.49% Upside)
Blogger Sentiment
Neutral
QTRX Sentiment 50%
Sector Average 66%
Sector Average 66%
Hedge Fund Trend
Increased
By 1.5M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $286.4K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▼ 1.0%
Last 30 Days ▲ 12.6%
Last 30 Days ▲ 12.6%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-53.96%
12-Months-Change
Fundamentals
Return on Equity
-43.59%
Trailing 12-Months
Asset Growth
-14.90%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Quanterix Corporation
Quanterix Corporation, based in Billerica, Massachusetts, is a life sciences enterprise dedicated to pioneering and commercializing advanced digital immunoassay platforms. These sophisticated systems are designed to enhance precision health in both scientific research and diagnostic applications, reaching markets across North America, Europe, the Middle East, Africa, and the Asia Pacific regions. The company's core offerings include several innovative instruments: The HD-X instrument, which provides highly sensitive and automated multiplex protein detection. The SR-X instrument, enabling researchers to leverage Simoa detection technology for diverse uses, such as the direct detection of nucleic acids. The SP-X instrument, which utilizes Simoa planar array technology for conducting multiplex chemiluminescent immunoassays. Alongside these platforms, Quanterix also supplies crucial consumables, including assay kits and reagents. In addition to its product line, the company delivers various contract research services, encompassing sample analysis, the development of custom "homebrew" assays, and other specialized research and development projects. Quanterix's operational focus spans critical health areas like neurology, oncology, cardiology, infectious diseases, and inflammation. Its clientele within the life science research sector primarily consists of laboratories affiliated with academic and governmental research institutions, as well as pharmaceutical, biotechnology, and contract research organizations. Sales are managed through a multifaceted approach, combining a direct sales force, dedicated support organizations, and a network of distributors or sales agents. The company was initially incorporated in 2007 as Digital Genomics, Inc., before rebranding to Quanterix Corporation in August of the same year.
QTRX Company Deck
QTRX Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call balanced clear near-term challenges and a meaningful guide reduction against several operational and strategic positives. Management reported a sizable Q2 revenue shortfall and cut full-year revenue guidance materially, delaying cash-flow break-even to 2027, which are significant negatives. Offsetting this, the company preserved cash, completed Akoya integration and $85M of synergies, achieved substantial non-GAAP gross margin improvement, showed sequential bookings momentum (book-to-bill 1:1), secured important reimbursements and coverage wins for its LucentAD diagnostic (CMS pricing and Anthem coverage), launched new assays and Spatial products, and added experienced commercial and diagnostics leadership while reorganizing sales for improved execution. Overall, positives and active corrective actions are substantial but are currently counterbalanced by the material revenue shortfall, segment weakness, and near-term financial impacts.View all QTRX earnings summariesQTRX Stock 12 Month Forecast
Average Price Target
$3.25
▲(16.49% Upside)
Technical Analysis
Ownership Overview
6.83% Insiders
19.57% Mutual Funds
1.38% Other Institutional Investors
61.57% Public Companies and
Individual Investors